home icon user icon
Welcome to International Network for Natural Sciences | INNS Pub.
Home My Account
Submit Manuscript
double_slash
breadcumb_bg

Evaluation of hepatotoxicity induced by colorectal cancer chemotherapy in an Algerian population

Paper Details

Research Paper 01/02/2020
Views (336) Download (18)
current_issue_feature_image
publication_file

Evaluation of hepatotoxicity induced by colorectal cancer chemotherapy in an Algerian population

Haoud Khadidja, Mellali Sarah, Kerouaz Lilia, Merhoul Fatima Zohra, Kebir Rajaa
Int. J. Biosci.16( 2), 241-251, February 2020.
Certificate: IJB 2020 [Generate Certificate]
Key: ChemotherapyColorectal cancerHepatotoxicity

Abstract

Colorectal Cancer (CRC) is a malignant tumor that originates in the cells of the colon or rectum. Chemotherapy, alone or combined with other treatments, have largely contributed to the improvement of the survival of the patients, however their side effects can appear at any time in particular liver damage. The objective of our study was to evaluate the toxicity of treatments used in chemotherapy of CRC, and more particularly to determine their hepatotoxicity. For this purpose, we carried out a retrospective analytical epidemiological study, going from February to May 2019, including 109 patients with CRC and undergoing anticancer chemotherapy at the Anti Cancer Center (CAC) of Sidi Bel Abbes. Our patients developed hepatotoxicity in 43.04% of cases, resulting in increased levels of liver parameters, transaminases, alkaline phosphatase, gamma GT, total and direct bilirubin’s. Our work suggests that the anti-cancer therapies used may be responsible for hepatotoxicity; This shows that dosage adjustment and established prevention measures are insufficient.

VIEWS 23
Cover PDF

Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR. 2004. Recurrence and outcomes following hepatic resection, radiofrequency ablation and combined resection/ablation for colorectal liver metastases. Annals of Surgery 239: 818-25; discussion 825-17.

Allemani C, Coleman MP. 2017. Public health surveillance of cancer survival in the United States and worldwide: the contribution of the CONCORD programme. Cancer 123, 4977–4981. http://dx.doi.org/10.1002/cncr. 30854.

Amegbor K, Napo-Koura GA, Songne – Gnamkoulamba B, Redah D, Tekou A. 2008. Aspects épidémiologiques et anatomopathologiques des tumeurs du tube digestif au Togo. Gastroentérologie Clinique et Biologique 32(4), 430-434.

Arfa N, Hamdani L, Gharbi L, Ben Abid S, Ghariani B. 2006. Survie et facteurs pronostiques des adénocarcinomes colorectaux : étude analytique uni multifactorielle de 150 cas, Elsevier Masson, Annales de chirurgie 131, 104-111.

Arotcarena R, Calès V, Berthelemy PH. 2006. Severe sinusoidal lesions: a serious and overlooked complication of oxaliplatin-containing chemotherapy? Gastroentérologiecliniqueetbiologique 30(13), 13–6.

Ballinger AB, Anggiansah C. 2007. Colorectal cancer. British Medical Journal 335, 715-718.

Baumgaertner V, Ratziu JC, Vaillant L, Hannoun T, Poynard T. 2010. Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review. Bulletin Cancer 97(5), 559-69. http://dx.doi.org/10.1684/bdc.2010.1049.

Belot A, Grosclaude P, Bossard N. 2008. Cancer incidence and mortality in France over the period 1980-2005. Revue Epidemiologie Santé Publique 56, 159-75.

Benelkhaiat R, Rabbani K, Nasrollah N, Finech B, Louzi A, El Dafali A. 2010. Les cancers digestifs dans la région de Marrakech. African Journal of Cancer 2, 160-165.

Brouquet A, Benoist S, Julie C, Penna C, Beauchet A. 2009. Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 145(4), 362–71.

Bubalo J, Warden BA, Wiegel JJ, Nishida T, Handel E. 2014. Does applying technology throughout the medication use process improve patient safety with antineoplastics? Journal of Oncology Pharmacy Practice 20, 445–460.

Chaput U, Coriat R, Terris B, Brezault C, Chaussade S. 2008. Syndrome d’obstruction sinusoïdale après chimiothérapie adjuvante par Folfox. Gastroentérologie Clinique et Biologique 32,  992—994.

Chen K, Gong Y, Zhang Q, Shen Y, Zhou T. 2016. “Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis”. Medicine. 95(46), e5221.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A. 2004.  Cetuximabmonotherapy and cetuximab plus irinotecan in irinotecan-refractory. New England Journal of Medicine 351, 337-45.

de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy T. 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 18, 2938-47.

Desjardin M. 2014. Facteurs de risque et impact clinique de l’hépatotoxicité des chimiothérapies dans lecancer colorectal métastatique. Médecine humaine et pathologie. http://dx.doi.org/dumas-01089116

Dickens E, Ahmed S. 2018. Principles of cancer treatment by chemotherapy. Surgery (United Kingdom) 36(3), p 134-138.

Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P. 2000. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentrerandomised trial. Lancet; 355: 1041-7.

Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. 2004. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgery 240, 438-47; discussion 447-50.

Gambiez L, Denimal F, Karoui M, Dewailly V,  Pruvot FR et Quandalle P. 1999. Adjuvant intra-arterialchemotherapyafter curative resection of livermetastasisfrom colorectal cancer. Results of a pilot studyin 30 patients. Chirurgie; 124(6), 640-8.

GLOBOCAN. 2000. Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no 5.Lyon, France: IARC Press, 2001.

Goldspiel B, Hoffman NL, Griffith S, Goodin R, DeChristoforo. 2015. ASHP guidelines on preventing medication errors with chemotherapy and biotherapy. The American Journal of Health-System Pharmacy 72, e6–e35.

Grenet J. 2018. L’information du patient atteint de cancer : principes et focus sur les effets indésirables de la chimiothérapie. Sciences pharmaceutiques. Dumas-01932631.

Haggar FA, Boushey RP. 2009. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clinics in Colon and Rectal Surgery 22, 191-7.

Housse EL, Ajbara W, Amsaguine S, El Amrani N. 2015. Profils épidémiologique et anatomoclinique d’une population marocaine atteinte de cancer colorectal. African Journal of Cancer 2, 95-99.

Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B. 2008. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. European Journal of Surgical Oncology 34(11), 1231-6. http://dx.doi.org/10.1016/j.ejso.2008.01.001.

Letonturier P. 2008. Colorectal cancer, form detection to treatment. La Presse Médicale 37(10), 1525-1527.

Maamri A. 2015. Données épidémiologiques sur le cancer dans le monde et au Maroc. Revue bibliographique. Annales des Sciences de la Santé 1, 20-29.

Makin G. 2018. Principles of chemotherapy. Paediatrics and Child Health (United Kingdom) 28(4), p 183-188.

Mattsson TO, Holm B, Michelsen B, Knudsen JL, Brixen K. 2011. Nonintercepted dose errors in prescribing anti-neoplastic treatment: a prospective, comparative cohort study. Annals of Oncology 26, 981–986.

McWhirter D, Kitteringham N, Jones RP, Malik H, Park K, Palmer D. 2013.  Chemotherapy induced hepatotoxicity in metastatic colorectal cancer: a review of mechanisms and outcomes. Critical Reviews in Oncology/Hematology. 88, 404–415. http://dx.doi.org/10.1016/j.critrevonc.2013.05.011.

Mikalauskas S, Mikalauskiene L, Bruns H, Nickkholgh A, Hoffmann K. 2011. Dietary glycine protects from chemotherapyinduced hepatotoxicity. Amino Acids 40, 1139–1150. http://dx.doi.org/10.1007/s00726-010-0737-6.

Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C. 2005. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Annals of Surgery 241, 715-22, discussion 722-14.

Tebibel S, Zouaghi Y, Atallah S, Mechati C, Sabre M, Kabbouche S. 2014. Colorectal cancer: Epidemiological study, clinical, pathological an immunohistochemical Examination in patients of Eastern Algeria. International Journal of Pharmaceutical Sciences Review and Research 26(2), 13-18.

Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery- Mignard D. 2004. Folfiri followed by Folfox-6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Journal of Clinial Oncology 22, 229-37.

Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D. 2004. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Oncology 22, 229-237.

Vargas GM, Sheffield MK, Parmar DA, Han Y, Gajjar H. 2014. Trends in Treatment and Survival in Older Patients Presentingwith Stage IV Colorectal Cancer. Journal of Gastrointestinal Surgery 18(2), 369–377.

Zheng R, Du M, Zhang B, Xin J, Chu H, Ni M, Zhang Z, Gu D, Wang M. 2018. Body mass index (BMI) trajectories and risk of colorectalcancer in the PLCO cohort. British Journal of Cancer119, 130–132.

Submit Manuscript